Astrazeneca ADR Stock
-
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | 0.000% | -2.092% | -7.327% | 28.571% | 11.962% | 46.250% | 22.353% |
| Bayer AG ADR | -4.900% | 3.209% | -20.902% | 73.874% | 9.659% | -30.072% | -26.336% |
| Teva Pharmaceutical Industries Ltd ADR | 2.730% | -5.882% | -10.490% | 70.100% | -4.833% | 219.202% | 174.384% |
News
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable

